Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Clinical Characteristics of Severe Acute Chest Syndrome in Children with Sickle Cell Disease

Shaniqua C. Johnson, Venee N. Tubman, Titilope Fasipe, Julie P. Katkin, Nicholas Ettinger, Jonathan M. Flanagan

Blood (2021) 138 (Supplement 1): 4175.

https://doi.org/10.1182/blood-2021-150906

Published: 2021

Journal Articles

Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies

Bijal D. Shah, Caron Jacobson, Scott R. Solomon, Nitin Jain, Mark C. Johnson, Monika Vainorius, Lou Yu, Christopher R. Heery, Alan F. List, Fiona He, Ran Reshef, Luke P. Akard, Craig S. Sauter, Adam J. Olszewski, Abhinav Deol, Koen van Besien

Blood (2021) 138 (Supplement 1): 302.

https://doi.org/10.1182/blood-2021-150609

Published: 2021

Journal Articles

Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic 'Off-the-Shelf' CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL

Nitin Jain, Hagop Kantarjian, Scott R. Solomon, Fiona He, Craig S. Sauter, Christopher R. Heery, Alan F. List, Mark C. Johnson, Yu Lou, Monika Vainorius, Koen van Besien, Adam J. Olszewski, Anthony S. Stein, Bijal D. Shah

Blood (2021) 138 (Supplement 1): 650.

https://doi.org/10.1182/blood-2021-153166

Published: 2021

Journal Articles

The genomic landscape of plasma cells in systemic light chain amyloidosis

Blood (2018) 132 (26): 2775–2777.

https://doi.org/10.1182/blood-2018-08-872226

Published: 2018

Includes: Supplemental data

Journal Articles

Subclonal TP53 copy number is associated with prognosis in multiple myeloma

Blood (2018) 132 (23): 2465–2469.

https://doi.org/10.1182/blood-2018-06-857250

Published: 2018

Includes: Supplemental data

Journal Articles

Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials

Blood (2018) 132 (Supplement 1): 2000.

https://doi.org/10.1182/blood-2018-99-110149

Published: 2018

Journal Articles

The Mutational Landscape of Relapse in High Risk Myeloma Is Significantly Impacted By the Depth of Response but Not Maintenance Lenalidomide

Blood (2017) 130 (Supplement 1): 396.

https://doi.org/10.1182/blood.V130.Suppl_1.396.396

Published: 2017

Journal Articles

Molecular Characterisation of TP53 Aberrations in 1,777 Myeloma Trial Patients

Blood (2017) 130 (Supplement 1): 4331.

https://doi.org/10.1182/blood.V130.Suppl_1.4331.4331

Published: 2017

Journal Articles

The Novel Protein HSF1 Stress Pathway Inhibitor Bisamide CCT361814 Demonstrates Pre-Clinical Anti-Tumor Activity in Myeloma

Karen Menezes, PhD BSc, MSc, Grace Aram, MSc, Fabio Mirabella, PhD, David C Johnson, PhD, Amy L Sherborne, PhD, Richard S Houlston, MD PhD, Matthew D Cheeseman, PhD, Elisa Pasqua, PhD, Paul Clarke, PhD, Paul Workman, PhD, Keith Jones, PhD, Martin F Kaiser, MD

Blood (2017) 130 (Supplement 1): 3072.

https://doi.org/10.1182/blood.V130.Suppl_1.3072.3072

Published: 2017

Journal Articles

Molecular Profiling of Relapsed and Refractory Myeloma Identifies Frequent Bi-Allelic Driver Events — Interim Results of the 'Myeloma UK Seven' Biomarker Trial

Amy L Sherborne, PhD, Vallari Shah, MBBS, Andrew Hall, Katrina Walker, Sidra Ellis, Farzana Begum, David C Johnson, James Croft, BSc, MBBS, MRCP, Jack Kendall, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Lilit Atanesyan, Suvi Savola, Louise Flanagan, Anjan Thakurta, PhD, Mamta Garg, MD, Gordon Cook, MD PhD, Kevin Boyd, Sarah Brown, Martin F Kaiser, MD

Blood (2017) 130 (Supplement 1): 1851.

https://doi.org/10.1182/blood.V130.Suppl_1.1851.1851

Published: 2017

Journal Articles

Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial

Amy L Sherborne, PhD, Vallari Shah, MBBS, Sidra Ellis, Farzana Begum, Jack Kendall, David C Johnson, Roger G Owen, MD, Mark T Drayson, MD PhD, Louise Flanagan, Debbie Sherratt, Walter M Gregory, PhD, Graham Jackson, MDPhD, Guy Pratt, MD FRCP, FRCPath, Gordon Cook, MD PhD, Samantha Hinsley, Sarah Brown, Matthew W Jenner, Martin F Kaiser, MD

Blood (2017) 130 (Supplement 1): 1767.

https://doi.org/10.1182/blood.V130.Suppl_1.1767.1767

Published: 2017

Journal Articles

Neutral tumor evolution in myeloma is associated with poor prognosis

David C. Johnson, Oleg Lenive, Jonathan Mitchell, Graham Jackson, Roger Owen, Mark Drayson, Gordon Cook, John R. Jones, Charlotte Pawlyn, Faith E. Davies, Brian A. Walker, Christopher Wardell, Walter M. Gregory, David Cairns, Gareth J. Morgan, Richard S. Houlston, Martin F. Kaiser

Blood (2017) 130 (14): 1639–1643.

https://doi.org/10.1182/blood-2016-11-750612

Published: 2017

Includes: Supplemental data

Journal Articles

Identifying Ultra-High Risk Myeloma By Integrated Molecular Genetic and Gene Expression Profiling

Blood (2016) 128 (22): 4407.

https://doi.org/10.1182/blood.V128.22.4407.4407

Published: 2016

Journal Articles

DNA Methylation Profiling of Myeloma Trial Patients Reveals Specific Epigenetic Changes Associated with Outcome

Blood (2016) 128 (22): 804.

https://doi.org/10.1182/blood.V128.22.804.804

Published: 2016

Journal Articles

Specific Identification of High Risk Disease Using Molecular Profiling By Mymap (Myeloma MLPA and translocation PCR) of 1,036 Cases

Martin F Kaiser, MD, Eileen Mary Boyle, MD PhD, Brian A Walker, PhD, Dil B Begum, Paula Proszek, David C Johnson, PhD, Charlotte Pawlyn, MB BChir, John R Jones, MD, Suvi Savola, PhD, Roger G Owen, Mark T Drayson, MD PhD, David A Cairns, Gordon Cook, MD PhD, Walter M Gregory, Richard S Houlston, MDPhDFRCP, Faith E Davies, MD, Graham H Jackson, MD, Gareth J Morgan, MD PhD

Blood (2015) 126 (23): 2981.

https://doi.org/10.1182/blood.V126.23.2981.2981

Published: 2015

Journal Articles

Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing

Blood (2015) 126 (23): 371.

https://doi.org/10.1182/blood.V126.23.371.371

Published: 2015

Journal Articles

Molecular Subgroups of Hyperdiploidy and Their Prognostic Relevance - an Analysis of 1,036 Myeloma Trial Patients

Blood (2015) 126 (23): 2983.

https://doi.org/10.1182/blood.V126.23.2983.2983

Published: 2015

Journal Articles

Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma

Blood (2014) 124 (21): 723.

https://doi.org/10.1182/blood.V124.21.723.723

Published: 2014

Journal Articles

Mutational Patterns and Copy Number Changes at Diagnosis Are a Powerful Tool to Predict Outcome: Result of the Sequencing Study of 463 Newly Diagnosed Myeloma Trial Patients

Blood (2014) 124 (21): 637.

https://doi.org/10.1182/blood.V124.21.637.637

Published: 2014

Journal Articles

The Extent of Intra-Clonal Genetic Diversity within the Myeloma Clone Is a Predictive Biomarker of Progression and Outcome after Treatment

Blood (2014) 124 (21): 640.

https://doi.org/10.1182/blood.V124.21.640.640

Published: 2014

NARROW

Clinical Characteristics of Severe Acute Chest Syndrome in Children with Sickle Cell Disease

Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies

Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic 'Off-the-Shelf' CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL

The genomic landscape of plasma cells in systemic light chain amyloidosis

Subclonal TP53 copy number is associated with prognosis in multiple myeloma

Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials

The Mutational Landscape of Relapse in High Risk Myeloma Is Significantly Impacted By the Depth of Response but Not Maintenance Lenalidomide

Molecular Characterisation of TP53 Aberrations in 1,777 Myeloma Trial Patients

The Novel Protein HSF1 Stress Pathway Inhibitor Bisamide CCT361814 Demonstrates Pre-Clinical Anti-Tumor Activity in Myeloma

Molecular Profiling of Relapsed and Refractory Myeloma Identifies Frequent Bi-Allelic Driver Events — Interim Results of the 'Myeloma UK Seven' Biomarker Trial

Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial

Neutral tumor evolution in myeloma is associated with poor prognosis

Identifying Ultra-High Risk Myeloma By Integrated Molecular Genetic and Gene Expression Profiling

DNA Methylation Profiling of Myeloma Trial Patients Reveals Specific Epigenetic Changes Associated with Outcome

Specific Identification of High Risk Disease Using Molecular Profiling By Mymap (Myeloma MLPA and translocation PCR) of 1,036 Cases

Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing

Molecular Subgroups of Hyperdiploidy and Their Prognostic Relevance - an Analysis of 1,036 Myeloma Trial Patients

Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma

Mutational Patterns and Copy Number Changes at Diagnosis Are a Powerful Tool to Predict Outcome: Result of the Sequencing Study of 463 Newly Diagnosed Myeloma Trial Patients

The Extent of Intra-Clonal Genetic Diversity within the Myeloma Clone Is a Predictive Biomarker of Progression and Outcome after Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only